First Patient Dosed in First-in-human trial of AGX101, a Novel ADC targeting TM4SF1

A first patient has been dosed in a Phase 1 clinical study (NCT06440005) with AGX101, a novel TM4SF1-directed Nuclear-Delivered Antibody-Drug Conjugate™ (ND-ADC) therapy for the treatment of solid tumors. AGX101, which is being developed by privately held biotech startup Angiex, is based on a new, groundbreaking ADC technology platform with a unique mechanisms of action.